Structural optimization of adaptaquin, a HIF prolyl hydroxylase inhibitor


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

The structural optimization of adaptaquin, viz., 7-(4-chlorophenyl)[(3-hydroxypyridin-2-yl)amino]methylquinolin-8-ol, a HIF (hypoxia inducible factor) prolyl hydroxylase inhibitor, was carried out. This was done by cell-based screening using cell lines stably expressing a reporter construct consisting of the fusion protein of HIF oxygen-dependent domain and firefly luciferase (HIF1 ODD-luc). More than 100 structural analogs of adaptaquin were screened and the structures active in the submicromolar range were selected. The highest activity was found for analogs containing isobutyl, isopropyl, trifluoromethyl, and nitro group or halogen atom in the para-position of the benzene ring, but not a dimethylamino group or more bulky substituents. The lack of dependence on the donor-acceptor properties of substituents attests to predominance of the steric effect. The presence of methyl group in positions 3 and 5 of the pyridine ring provides additional activation. The 2-methyl group present in the hydroxyquinoline scaffold (50 compounds in the set) prevents coordination of the inhibitor in the active site and significantly reduces the activation. According to the real-time PCR results, the newly improved adaptaquin analog induces HIF target genes 15-times more efficiently than the FG-4592 inhibitor developed by Fibrogen.

作者简介

A. Osipyants

Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology, and Immunology

Email: andrey.poloznikov@fccho-moscow.ru
俄罗斯联邦, 1 ul. Samory Mashela, Moscow, 117997

V. Tishkov

Department of Chemistry, M. V. Lomonosov Moscow State University; Innovations and High Technologies MSU Ltd.; A. N. Bach Institute of Biochemistry, Russian Academy of Sciences, Federal Research Center “Fundamentals of Biotechnology”

Email: andrey.poloznikov@fccho-moscow.ru
俄罗斯联邦, Build 3, 1 Leninskie Gory, Moscow, 119991; 16 ul. Tsymlyanskaya, Moscow, 109451; Build. 2, 33 Leninsky prosp., Moscow, 119071

I. Gazaryan

Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology, and Immunology; Department of Chemistry, M. V. Lomonosov Moscow State University

Email: andrey.poloznikov@fccho-moscow.ru
俄罗斯联邦, 1 ul. Samory Mashela, Moscow, 117997; Build 3, 1 Leninskie Gory, Moscow, 119991

A. Poloznikov

Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology, and Immunology; National Medical Research Radiological Center, Ministry of Health of the Russian Federation

编辑信件的主要联系方式.
Email: andrey.poloznikov@fccho-moscow.ru
俄罗斯联邦, 1 ul. Samory Mashela, Moscow, 117997; 4 ul. Koroleva, Obninsk, 249036

A. Khristichenko

Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology, and Immunology

Email: andrey.poloznikov@fccho-moscow.ru
俄罗斯联邦, 1 ul. Samory Mashela, Moscow, 117997

N. Smirnova

Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology, and Immunology

Email: andrey.poloznikov@fccho-moscow.ru
俄罗斯联邦, 1 ul. Samory Mashela, Moscow, 117997

D. Hushpulian

Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology, and Immunology

Email: andrey.poloznikov@fccho-moscow.ru
俄罗斯联邦, 1 ul. Samory Mashela, Moscow, 117997

I. Gaisina

Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago

Email: andrey.poloznikov@fccho-moscow.ru
美国, 833 South Wood, Chicago, IL, 60612

补充文件

附件文件
动作
1. JATS XML

版权所有 © Springer Science+Business Media, LLC, part of Springer Nature, 2019